Successful Treatment of Helicobacter Pylori-Negative Gastric MALT Lymphoma With Rituximab |
| |
| Authors: | Nadeem Chaudhary MD Howard Ozer David Huard MD Stan Lightfoot MD Sikandar Mesiya MD |
| |
| Affiliation: | (1) Divisions of Gastroenterology and Oncology, Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA;(2) Divisions of Gastroenterology and Oncology, Department of Radiology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA;(3) Divisions of Gastroenterology and Oncology, Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA;(4) Digestive Disease Specialists Inc., Oklahoma City, Oklahoma, USA;(5) Digestive Disease Specialists Inc., M.D. Medical Tower, 8121 National Ave, Suite 303, Midwest City, OK, 73110 |
| |
| Abstract: | Helicobacter pylori infection is strongly associated with low-grade gastric lymphoma, commonly known as mucosa-associated lymphoid tissue (MALT) lymphoma. H. pylori eradication leads to complete remission in 80% of early stage MALT lymphomas. The treatment for early stage H. pylori-negative gastric MALT lymphoma is evolving. Rituximab, a chimeric anti-CD20 antibody, has shown response rates of approximately 50% with minimal toxicity in patients with B-cell non-Hodgkin lymphoma. We describe herein the clinical, endoscopic, and histologic features of a patient with H. pylori-negative gastric MALT lymphoma treated successfully with rituximab. |
| |
| Keywords: | gastric mucosal associated lymphoid tissue (MALT) lymphoma Helicobacter pylori (H. pylori) rituximab |
| 本文献已被 PubMed SpringerLink 等数据库收录！ |
|
